oligonucleotide microarray situ hybridization plus kit (Agilent technologies)
Structured Review
Oligonucleotide Microarray Situ Hybridization Plus Kit, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hybridization+oligonucleotide+microarray/pmc03399218-33-7-6
Average 90 stars, based on 1 article reviews
Images
Related Articles
Hybridization:Article Title: Expanding the phenotype of X-linked SSR4-CDG: Connective tissue implications. Article Snippet: Signal sequence receptor protein 4 (SSR4) is a subunit of the translocon-associated protein (TRAP) complex, which participates in the translocation of proteins across the endoplasmic reticulum membrane, enhancing the efficiency of N-linked glycosylation. Microarray:Article Title: Expanding the phenotype of X-linked SSR4-CDG: Connective tissue implications. Article Snippet: Signal sequence receptor protein 4 (SSR4) is a subunit of the translocon-associated protein (TRAP) complex, which participates in the translocation of proteins across the endoplasmic reticulum membrane, enhancing the efficiency of N-linked glycosylation. |
![Association of immune marker signatures with PSA response and OS. (A) The correlations between the 24 non-redundant (ie, those without high Spearman correlations among each other) set of evaluated tumor immune microenvironment gene expression signatures (ρ is shown), (B) OS of the group with tumor immune gene expression signature analysis is not significantly different from the overall cohort of Lu-PSMA therapy treated patients at our institution and (C) the <t>cDNA</t> yield from RNA extracted from tumor samples, best PSA response and relative expression signature level (z-scores, higher values indicate higher signature) of immune-related gene signatures are shown correspondingly to identify patterns of signatures with regard to PSA response. Patients with higher PD-L2 signature (above the median) have longer OS time (D) and greater PSA responses (E). Lu-PSMA, [ 177 Lu]Lutetium-PSMA-617; mo., months; OS, overall survival; PD-L1, programmed death-ligand 1; PSA, prostate-specific antigen.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_3337/pmc10603337/pmc10603337__jitc-2023-007354f01.jpg)
